ANDA 202238, held by Impax Labs Inc. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 202238 (Guanfacine Hydrochloride), held by Impax Labs Inc, was first approved by FDA on Oct 20, 2015, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 20, 2015 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Discontinued |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Discontinued |
| Guanfacine HydrochlorideEQ 3MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Discontinued |
| Guanfacine HydrochlorideEQ 4MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Discontinued |
| Jul 18, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 20, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters